Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
106 hedge funds and large institutions have $186M invested in Cymabay Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 28 closing their positions.
132% more call options, than puts
Call options by funds: $801K | Put options by funds: $345K
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
10% less funds holding
Funds holding: 118 → 106 (-12)
13% less capital invested
Capital invested by funds: $213M → $186M (-$27.1M)
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$3.76M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$2.87M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.79M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.71M |
| 5 |
Millennium Management
New York
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$8.39M |
| 2 |
JP Morgan Chase
New York
|
-$3.11M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.39M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.38M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.44M |
CBAY Hedge Fund Activity: Q2 2022 in Review
106 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2022, worth a combined $186M — down 13% from $213M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of CBAY and 20 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 30 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $3.76M. The largest seller was BlackRock, cutting an estimated $8.39M.
- 106 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2022, down from 118 in Q1 2022.
- Funds reported $186M of Cymabay Therapeutics stock for Q2 2022, down 13% quarter-over-quarter.
- 20 funds opened new Cymabay Therapeutics positions in Q2 2022 and 28 closed out, a net change of -8 holders.
- The largest Cymabay Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $3.76M added.
- The largest Cymabay Therapeutics seller in Q2 2022 was BlackRock, an estimated $8.39M sold.
Based on aggregated 13F filings for Q2 2022.